Amylyx Pharmaceuticals, Inc. (AMLX)
Company Info
ISIN | US03237H1014 |
---|---|
CUSIP | 03237H101 |
Sector | Healthcare |
Industry | Biotechnology |
Highlights
Market Cap | $138.05M |
---|---|
EPS | $0.70 |
PE Ratio | 2.90 |
Revenue (TTM) | $380.79M |
Gross Profit (TTM) | -$74.21M |
EBITDA (TTM) | $39.89M |
Year Range | $1.70 - $30.50 |
Target Price | $4.25 |
Short % | 10.54% |
Short Ratio | 2.43 |
Share Price Chart
Loading data...
Compare to other instruments
Search for stocks, ETFs, and funds for a quick comparison or use the comparison tool for more options.
Performance
Performance Chart
The chart shows the growth of an initial investment of $10,000 in Amylyx Pharmaceuticals, Inc., comparing it to the performance of the S&P 500 index or another benchmark. All prices have been adjusted for splits and dividends.
Returns By Period
Amylyx Pharmaceuticals, Inc. had a return of -86.21% year-to-date (YTD) and -92.68% in the last 12 months.
Period | Return | Benchmark |
---|---|---|
Year-To-Date | -86.21% | 7.50% |
1 month | -22.81% | -1.61% |
6 months | -88.99% | 17.65% |
1 year | -92.68% | 26.26% |
5 years (annualized) | N/A | 11.73% |
10 years (annualized) | N/A | 10.64% |
Monthly Returns Heatmap
Jan | Feb | Mar | Apr | May | Jun | Jul | Aug | Sep | Oct | Nov | Dec | |
---|---|---|---|---|---|---|---|---|---|---|---|---|
2024 | 8.70% | 17.81% | -84.93% | -36.27% | ||||||||
2023 | -10.92% | -13.18% | 3.95% |
Risk-Adjusted Performance
Risk-Adjusted Performance Rank
The current rank of AMLX is 3, indicating that it is in the bottom 3% of the market in terms of risk-adjusted performance. This ranking is based on the combined values of the indicators listed below.
Amylyx Pharmaceuticals, Inc.(AMLX)
Risk-Adjusted Performance Indicators
The charts below present risk-adjusted performance metrics for Amylyx Pharmaceuticals, Inc. (AMLX) and compare them to a chosen benchmark (^GSPC). These indicators evaluate an investment's returns against its associated risks.
Dividends
Dividend History
Drawdowns
Drawdowns Chart
The Drawdowns chart displays portfolio losses from any high point along the way.
Worst Drawdowns
The table below displays the maximum drawdowns of the Amylyx Pharmaceuticals, Inc.. A maximum drawdown is a measure of risk, indicating the largest reduction in portfolio value due to a series of losing trades.
The maximum drawdown for the Amylyx Pharmaceuticals, Inc. was 95.70%, occurring on Apr 26, 2024. The portfolio has not yet recovered.
The current Amylyx Pharmaceuticals, Inc. drawdown is 95.04%.
Depth | Start | To Bottom | Bottom | To Recover | End | Total |
---|---|---|---|---|---|---|
-95.7% | Jan 30, 2023 | 313 | Apr 26, 2024 | — | — | — |
-79.18% | Mar 1, 2022 | 51 | May 11, 2022 | 104 | Oct 10, 2022 | 155 |
-17.59% | Feb 2, 2022 | 8 | Feb 11, 2022 | 5 | Feb 18, 2022 | 13 |
-15.23% | Dec 2, 2022 | 12 | Dec 19, 2022 | 23 | Jan 24, 2023 | 35 |
-13.39% | Oct 27, 2022 | 8 | Nov 7, 2022 | 13 | Nov 25, 2022 | 21 |
Volatility
Volatility Chart
The current Amylyx Pharmaceuticals, Inc. volatility is 21.33%, representing the average percentage change in the investments's value, either up or down over the past month. The chart below shows the rolling one-month volatility.
Financials
Financial Performance
Income Statement
TTM | |
---|---|
Revenue | |
Total Revenue | 0.00 |
Cost Of Revenue | 0.00 |
Gross Profit | 0.00 |
Operating Expenses | |
Selling, General & Admin Expenses | 0.00 |
R&D Expenses | 0.00 |
Total Operating Expenses | 0.00 |
Income | |
Income Before Tax | 0.00 |
Operating Income | 0.00 |
EBIT | 0.00 |
Earnings From Continuing Operations | 0.00 |
Net Income | 0.00 |
Income Tax Expense | 0.00 |
Interest Expense | 0.00 |
Other Non-Operating Income (Expenses) | 0.00 |
Extraordinary Items | 0.00 |
Discontinued Operations | 0.00 |
Effect Of Accounting Charges | 0.00 |
Non Recurring | 0.00 |
Minority Interest | 0.00 |
Other Items | 0.00 |